Retropharyngeal Abscess Market Analysis

Global Retropharyngeal Abscess Market Overview 

Retropharyngeal Abscess Market Size was valued at USD 0.38 Billion in 2023. The Global Retropharyngeal Abscess industry is projected to grow from USD 0.43 Billion in 2024 to USD 0.59 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.12% during the forecast period (2024 - 2032).

A retropharyngeal abscess is a serious infection, usually starts in the lymph nodes, characterised by collection of pus at the back of the throat. Retropharyngeal abscess typically occurs in children under the age of eight, sometimes it can also affect adults. The symptoms of retropharyngeal abscess include difficulty or noisy breathing, difficulty and pain while swallowing, drooling, severe cough, severe throat pain, neck stiffness or swelling, muscle spasms in the neck among others. Retropharyngeal abscess is generally preceded by upper respiratory infections mostly a middle ear or sinus infection.

The causes of retropharyngeal abscess are trauma or injury, medical procedure, dental procedures, alcohol intake, diabetes, cancer, AIDS, weakened immune system or a chronic diseases such as tuberculosis and others. Other complications indicated are pneumonia, blood clots in the jugular vein, mediastinitis, osteomyelitis and others. 

If left untreated, retropharyngeal abscess infection can spread to other parts of the body resulting in septic shock and organ failure. In severe instances, a retropharyngeal abscess can lead to death. The most common bacteria involved are Streptococcus, Staphylococcus, and others. Other infections, such as HIV and tuberculosis can also cause the retropharyngeal abscess. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications. Retropharyngeal abscess also slightly more common in males than females.

The market drivers for global retropharyngeal abscess market, are rise in demand due to the growing younger and susceptible population, increasing screening, urgency of the retropharyngeal abscess treatment, and rise in risk factors. The rise in cases of retropharyngeal abscess due to increase in Methicillin-resistant Staphylococcus aureus (MRSA) infections also stimulates the market. The market restraints are complications such as risk of bleeding, infections, pain, especially during surgery, high cost of retropharyngeal abscess treatment, lack of cardiac care infrastructure, and lack of focus on other diseases by the developing regions and others.

Global Retropharyngeal Abscess Market Segmentation 

The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.

Based on the diagnosis, the market of retropharyngeal abscess has been segmented as X-rays and computed tomography, blood tests, physical exam and others.

Based on the treatment, the market for retropharyngeal abscess has been segmented as calcium antibiotics, pain killers, surgical drainage and others.

Based on the market end user, the retropharyngeal abscess has been segmented as hospitals and clinics, research and academics and others.

Global Retropharyngeal Abscess Market Regional Analysis 

A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the market of retropharyngeal abscess. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. 

Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster market development of retropharyngeal abscess in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.

Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. 

The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.

Asia Pacific market of retropharyngeal abscess is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. 

The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. 

Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.

Key Players in the Global Retropharyngeal Abscess Market

Some of the key players profiled in the report are: 

• Merck KGaA


• Johnson & Johnson


• AstraZeneca plc


• Sanofi S.A.


• Pfizer


• Mylan N.V


• Novartis AG


• Teva pharmaceutical company


• GlaxoSmithKline plc.

Intended Audience

• Global Retropharyngeal abscess manufacturers & suppliers


• Research and development (R&D) companies


• Hospitals and clinics


• Academic institutes and universities